Business Context and Reporting Period
Company: Compass Therapeutics, Inc. (CMPX)
Filing Type: Form 8-K (Current Report)
Date: April 1, 2025
Event: Announcement of statistically significant top-line data for the primary endpoint of the COMPANION-002 Phase 2/3 randomized trial of tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer (BTC).
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The primary material change is the successful achievement of the primary efficacy endpoint in the COMPANION-002 study:
- Study Design: 168 adult patients randomized 2:1 to tovecimig + paclitaxel (n=111) or paclitaxel alone (n=57).
- Primary Endpoint (ORR):
- Tovecimig + Paclitaxel: 17.1% (19 of 111 patients), including one complete response.
- Paclitaxel Alone: 5.3% (3 of 57 patients).
- Statistical Significance: The 11.8% relative improvement was statistically significant (p=0.031).
- Secondary Endpoints: Data for Progression-Free Survival (PFS), Overall Survival (OS), and Duration of Response (DoR) are not yet mature. The company anticipates reaching the required event threshold in Q3 2025 and reporting secondary data in Q4 2025.
- Safety: The safety profile is consistent with prior studies. An independent Data Monitoring Committee (DMC) has reviewed data four times and recommended study continuation without modification.
Guidance, Outlook, and Risks
Outlook:
- The company expects to report detailed safety data and secondary endpoint analyses in the fourth quarter of 2025.
- A webcast was held on April 1, 2025, to review the data.
- The filing explicitly states that information in the press release and presentation (Exhibits 99.1 and 99.2) is not "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
- Secondary endpoint data remains immature and subject to future event triggers.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and the presentation (Exhibit 99.2) for detailed statistical tables not fully reproduced in the 8-K summary.
- Monitor the company's website for the webcast replay and any updates regarding the Q3 2025 event threshold for secondary endpoints.
- Review upcoming quarterly reports (10-Q/10-K) for financial impact, as this 8-K contains no financial data.
- Confirm the timeline for the Q4 2025 data readout for PFS, OS, and DoR.